<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273090</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL1112</org_study_id>
    <secondary_id>COG-ADVL1112</secondary_id>
    <nct_id>NCT01273090</nct_id>
  </id_info>
  <brief_title>Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth.

      PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat
      sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To estimate the maximum-tolerated dose (MTD) and/or recommended phase II dose of
           imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma.

        -  To define and describe the toxicities of imetelstat sodium.

        -  To characterize the pharmacokinetics of imetelstat sodium in children with refractory or
           recurrent solid tumors or lymphoma.

      Secondary

        -  To determine, in a preliminary manner, the antitumor effects of imetelstat sodium in
           children with refractory or recurrent solid tumors or lymphoma. (exploratory)

        -  To provide preliminary assessment of the biological activity of imetelstat sodium in
           children with recurrent or refractory malignancies by assessing telomerase activity,
           telomere length, hTERT protein, hTERT mRNA, and hTR levels in patient peripheral blood
           mononuclear cells (PBMNC) samples pretreatment and on treatment. (Exploratory)

        -  To assess telomerase activity, hTERT expression, telomere length, hTERT protein, hTERT
           mRNA, and hTR levels in patients' pretreatment tumor samples. (Exploratory)

      OUTLINE: This is a multicenter, dose-escalation study.

      Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every
      21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

      Patients undergo blood sample collection at baseline and periodically during study for
      pharmacokinetic and correlative studies. Tumor tissue samples from diagnosis and/or
      subsequent tumor resections or biopsies may also be collected for correlative studies.

      After completion of study therapy, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma</measure>
    <time_frame>21 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities of imetelstat sodium</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imetelstat sodium</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of refractory or recurrent solid tumors, including lymphoma

               -  No CNS tumors or known CNS metastases (Part A, dose escalation)

               -  CNS tumors or known CNS metastases allowed (Part B, maximum-tolerated dose or
                  recommended phase II dose)

                    -  No prior or concurrent CNS hemorrhage on a baseline MRI within the past 14
                       days

               -  All patients must have histologic verification of malignancy at original
                  diagnosis or relapse except for:

                    -  Intrinsic brain stem tumors

                    -  Optic pathway gliomas

                    -  Pineal tumors and elevations of CSF or serum tumor markers including
                       alpha-fetoprotein or beta-HCG

          -  Measurable or evaluable disease

          -  Disease for which there is no known curative therapy or therapy proven to prolong
             survival with an acceptable quality of life

          -  Patients with known bone marrow metastatic disease will be eligible for study provided
             they meet the blood count criteria and they are not known to be refractory to red cell
             or platelet transfusions

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) 50-100% (patients &gt; 16 years of age) OR Lansky PS
             50-100% (patients ≤ 16 years of age)

          -  ANC ≥ 1,000/mm³

          -  Platelet count ≥ 100,000/mm³ (transfusion-independent, defined as not receiving
             platelet transfusion within the past 7 days prior to enrollment)

          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR a serum creatinine based on
             age and/or gender as follows:

               -  0.6 mg/dL (1 to &lt; 2 years of age)

               -  0.8 mg/dL (2 to &lt; 6 years of age)

               -  1.0 mg/dL (6 to &lt; 10 years of age)

               -  1.2 mg/dL (10 to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)

          -  Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal (ULN)

          -  ALT ≤ 110 U/L (ULN for ALT is 45 U/L)

          -  Serum albumin ≥ 2 g/dL

          -  aPTT &lt; 1.2 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use an effective contraception method

          -  No uncontrolled infection

          -  No patients who, in the opinion of the investigator, may not be able to comply with
             the safety monitoring requirements of the study

        PRIOR CONCURRENT THERAPY:

          -  Recovered from acute toxic effects of all prior anti-cancer chemotherapy,
             immunotherapy, or radiotherapy

          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)

          -  At least 14 days since prior long-acting growth factor (e.g., Neulasta) or ≥ 7 days
             since prior short-acting growth factor

          -  At least 7 days since prior biologic or anti-neoplastic agent

          -  At least 6 weeks since any type of prior immunotherapy (e.g., tumor vaccines)

          -  At least 3 half-lives since last dose of a monoclonal antibody

          -  At least 2 weeks since prior local palliative radiotherapy (small port)

               -  At least 24 weeks since prior total-body irradiation, craniospinal radiotherapy,
                  or radiation to ≥ 50% of the pelvis

               -  At least 6 weeks since prior substantial bone marrow radiation

          -  At least 12 weeks since prior transplantation or stem cell infusion with no evidence
             of active graft vs host disease

          -  Prior and concurrent stable or decreasing dose of corticosteroids within the past 7
             days allowed

          -  No prior allogeneic transplant

          -  No other concurrent investigational drug

          -  No other concurrent anticancer agents including chemotherapy, radiotherapy,
             immunotherapy, or biologic therapy

          -  No concurrent cyclosporine, tacrolimus, or other agents to prevent either
             graft-versus-host disease post-bone marrow transplant or organ rejection
             post-transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick A. Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley's Children Cancer Center at Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood diffuse astrocytoma</keyword>
  <keyword>recurrent childhood fibrillary astrocytoma</keyword>
  <keyword>recurrent childhood gemistocytic astrocytoma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>recurrent childhood oligoastrocytoma</keyword>
  <keyword>recurrent childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood pilocytic astrocytoma</keyword>
  <keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
  <keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
  <keyword>recurrent childhood protoplasmic astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>childhood pineal parenchymal tumor</keyword>
  <keyword>recurrent childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>childhood nodular lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>hepatosplenic T-cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>noncutaneous extranodal lymphoma</keyword>
  <keyword>peripheral T-cell lymphoma</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>small intestine lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

